Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2021-04-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
第四届监事会第十七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of the company regarding the review and approval of the company's 2021 first quarter report. It states that the Supervisory Board has audited and approved the full quarterly report, confirming its compliance and accuracy. The document itself does not contain the financial statements or substantive financial data of the quarterly report but is an announcement of the Supervisory Board's approval of that report. The document length is short (551 characters), and it serves as a formal announcement rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a formal announcement related to regulatory compliance and report approval, not the actual Interim/Quarterly Report (IR).
2021-04-28 Chinese
独立董事关于第四届董事会第二十次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion regarding the appointment of senior management personnel at a specific board meeting of the company. It references compliance with company law, stock exchange guidelines, and company articles of association. The content focuses on management appointment and related compliance, without financial data or broader management discussion. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management. The document length is short and specific to management appointment, not a full report or announcement of a report publication.
2021-04-28 Chinese
第四届董事会第二十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from 福安药业 (Fuan Pharmaceutical Group Co., Ltd.) dated April 28, 2021. It reports the decisions made at the 20th meeting of the 4th board, including approval of the 2021 first quarter report and appointment of the general manager. The document is short (777 characters) and primarily announces board decisions rather than providing detailed financial data or the full quarterly report. It also references that the full quarterly report is published elsewhere. This fits the category of Board/Management Information (MANG) because it includes management appointment and board resolutions. It is not the full quarterly report (IR) itself, nor an earnings release or other report type. Therefore, the classification is MANG with high confidence.
2021-04-28 Chinese
2021年第一季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2021 年第一季度报告全文" which translates to "2021 First Quarter Report Full Text". It contains detailed financial data including income statement, balance sheet, cash flow statement, and management discussion on financial performance and business outlook for the first quarter of 2021. The document includes comprehensive financial metrics, explanations of changes in financial items, shareholder information, and fundraising usage details. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The content and structure clearly identify it as an Interim / Quarterly Report, which is a comprehensive financial report for a period shorter than a full fiscal year. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2021
2021-04-28 Chinese
2020年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement from the 2020 Annual General Meeting (AGM) of 福安药业 (Fuan Pharmaceutical Group Co., Ltd.). It details the voting results on various proposals including the 2020 annual reports, audit reports, profit distribution, and appointment of auditors. The document includes detailed voting outcomes and legal opinions on the meeting's validity. It does not contain the full annual report or financial statements but references that these reports were published earlier on the regulatory website. The document is essentially the official announcement of the voting results from the AGM, not the report itself. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is over 5,000 characters and contains detailed voting data, supporting this classification with high confidence.
2021-04-28 Chinese
2020年年度股东大会法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2020 Annual General Meeting (AGM) of 福安药业 (Fuan Pharmaceutical Group Co., Ltd.). It details the procedures of convening and holding the AGM, the qualifications of attendees, the voting procedures, and the results of various resolutions passed at the AGM. The document does not contain financial statements or detailed financial performance data but focuses on the legality and validity of the AGM process and resolutions. It is not the Annual Report itself, nor an audit report or earnings release. It is not a proxy solicitation or voting results announcement but a legal opinion related to the AGM. Given the content and purpose, this document best fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting. The document length (5781 characters) and detailed content support this classification with high confidence.
2021-04-28 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.